CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings

Snowflake

These companies made an early splash, but that doesn't mean they're a safe choice for investors.

The 3 Best-Performing IPOs of 2020

CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.

CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate

CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.

CVAC Stock: CureVac Pops on Plans for Phase 2 Vaccine Trials

Moderna

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals stock rose on positive data on its possible Covid-19 treatment, while shares of Moderna and CureVac stock rose as their possible Covid-19 vaccines made advances. The post Covid Report: Regeneron, Moderna, CureVac Up As Possible Coronavirus Cures Advance appeared first on Investor's Business Daily.

Covid Report: Regeneron, Moderna, CureVac Up As Possible Coronavirus Cures Advance

CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?

Germany Makes a $299 Million Bet on CureVac

These two stocks have made shareholders rich in a very short amount of time. Here's why new potential investors should stay away.

The Top 2 IPO Stocks to Avoid This September

BioNTech SE

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.

Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development

AstraZeneca

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Novavax

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. 
AstraZeneca (NYSE:AZN)
CureVac (NASDAQ:CVAC)
GlaxoSmithKline (NYSE:GSK)
Inovio (NASDAQ:INO)
Johnson & Johnson (NYSE:JNJ)
Moderna (NASDAQ:MRNA)
Novavax (NASDAQ:NVAX)
The post 7 Coronavirus Vaccine Stocks to Watch as Approval Nears appeared first on InvestorPlace.

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.

CureVac Stock Is Just Another Part of a Bigger Story

Pfizer

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

Teladoc

Veeva Systems

Investors should exercise caution before buying into these high-flying growth stocks.

3 Absurdly Overvalued Healthcare Stocks Investors Should Avoid

CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.

No Need to Rush Into CureVac Stock After Massive IPO Pop

Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?

Why Science and Economics Might Justify CureVac

Dynavax Technologies

Sorrento Therapeutics Inc

Vaxart

Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.

Got $3,000? These 4 Emerging Coronavirus Vaccine Stocks Look Like a Bargain

That money will also be used for its production.

CureVac Is Promised Up to $298 Million for Coronavirus Vaccine Development by Germany

Recent IPO and vaccine play CureVac stock could bounce back – but tread carefully. Much of the upside remains priced into shares.

Is CureVac a Buy on the Pullback? It Depends

Silicon Valley entrepreneur Elon Musk and German Economy Minister Peter Altmaier consider vaccine company CureVac as one the world's most innovative firms, a source said on Thursday, after Musk and Altmaier met on Wednesday.

Tesla's Musk considers CureVac as one of most innovative firms: source

The coronavirus vaccine play is crowded and CureVac stock needs to win more deals to get noticed
The post Why CureVac Might Soar From Here appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					America’s #1 Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company				
			
					
				
					Radical New Battery Could Dismantle Oil Markets

Why CureVac Might Soar From Here

CureVac stock has been hot since its IPO thanks to its coronavirus vaccine candidate. Here's why you should give CVAC a breather now.

Go Easy on CureVac Stock After Its Red-Hot Market Debut

CureVac has extensive collaborations globally as well as a range of drug candidates. CureVac stock is a high-risk, high-return investment.

CureVac Stock Has Been Hot Following Its Recent IPO

1Life Healthcare

Overstock.com

With market indices back to all-time highs, these three stocks may offer ample outperformance for investors in the long run.

Have $3,000? Buying These 3 Stocks Would Be the Smartest Move You Ever Made

CureVac stock soars after the company announced that it was in talks of supplying the vaccine to EU member states. 
The post CureVac Stock Soars After Talks of Supplying Vaccines for the EU appeared first on InvestorPlace.

CureVac Stock Soars After Talks of Supplying Vaccines for the EU

CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years.

CureVac Is a Bet on a Safe and Effective Vaccine

Two promising biotechs with COVID-19 vaccine candidates in development. One of them is the more likely winner.

Better Coronavirus Stock: CureVac vs. Moderna

Tiny CureVac, which popped in its IPO on Friday, announced Thursday it's close to inking a big contract with the European Commission for its coronavirus vaccine candidate. CVAC stock jumped.

News for CureVac B.V Stock (CVAC)